The Right to Try

“Right to Try” (Again): A history of the experimental therapy movement

 

In recent weeks and months, momentum has increased on Capitol Hill to craft “right to try” laws that would profoundly change the medical landscape. The national legislation will allow terminally ill patients more access to experimental therapies (drugs, biologics, devices) that have completed Phase 1 testing. Powerful pharmaceutical and biotech concerns have been largely quiet. The Trump administration, for its part, has underlined the issue, not only in the State of the Union Address but in VP Mike Pence’s active support.

Critics in academia and medical circles argue that the proposed “right to try” legislation would undermine public health and circumvent Food and Drug Administration (FDA) oversight, while supporters argue that severely ill patients ought to have more freedoms to take experimental pharmaceutical products. Current reportage of the movement has rightfully referenced the HIV epidemic, the film Dallas Buyers Club (2013), and the drive for improved access to unapproved drugs in the 1980s. However, these are not the only ways to view contemporary deliberations about the nation’s drug regulatory architecture.

The right to try movement – and any legislation – embody long-standing struggles about the most appropriate treatment for public and individual health. These struggles have pitted mainstream medical practitioners against interlopers, and regulators against drug companies.  Compassionate language about desperate patients with few options has run alongside intense legal wrangling, consumer activism, and prolonged discussions about the validity of medico-scientific data.

THE FULL POST CAN BE FOUND HERE

 

And a song called ‘Try Again’!

 

Advertisements

Radical Health

Bill Booth kindly invited me on to his podcast to discuss health and medicine. Bill is one of the founders of Radical Americas, an academic network for scholars and activists with interests in radicalism in the Western Hemisphere.

**

 

New Editors at Social History of Alcohol and Drugs

The ADHS is pleased to announce that the editorship of its journal, *The Social History of Alcohol and Drugs*, will be taken over by Prof. Nancy D. Campbell (Rensselaer Polytechnic Institute), Prof. David Herzberg (Buffalo) and Dr. Lucas Richert (Strathclyde). The society would also like to express its gratitude for the work that outgoing editor, […]

via New editors for SHAD — Alcohol and Drugs History Society

Big Pharma Round-Up V (#Cannabis edition)

https://twitter.com/DavidLenigas/status/948667879368642562

**

Large Indoor Marijuana Commercial Growing Operation With Fans, Greenhouse, Equipment For Growing High Quality Herb. Cannabis Field Growing For Legal Recreational Use in Washington State

To publish…

I wrote about Lambert Publishers last month. And they’ve come back at me again. They want to publish an article of mine. Lambert is, of course, a ‘predatory publisher,’ and the company is all about cashing in on other’s work.

Here’s what they wrote me earlier this month.

Again, I went to school for a long f****** time. I’m not super uptight about it, but get the salutation correct.

I’m told I should have some questions…why? Because publishing – i.e., with Lambert – is a major achievement. Love it.

I also love the closing line. All of us in this hyper competitive dog-eat-dog academic world find publishing “interesting.” Seriously.

Lambert is an interesting company…watch out.

**

Here’s another interesting Lambert.

 

Big Pharma Round-Up II

Here is a snapshot of the past week in Big Pharma news.  This is coming at you a little early because of the Christmas slowdown. Happy holidays.

To kick off:

The drug industry spent big!

Here’s another one on the lobbying money spent over the past months and years…

https://www.statnews.com/2017/12/19/pharma-lobbying-spending/

A lot of money was splashed out. ‘“Does that surprise you?” said Billy Tauzin, the former PhRMA CEO who ran the organization a decade ago as Obamacare loomed. Whenever Washington seems interested in limiting drug prices, he said, “PhRMA has always responded by increasing its resources.”’

*

In Canada, there’s efforts to reduce “sticker shock” when purchasing drugs.

http://www.cbc.ca/news/health/drug-cost-surprises-1.4454803

“A Toronto family doctor thinks she has a prescription for the nasty surprise many patients experience when they go to the pharmacy and learn just how much their medications will cost.”

*

What about other countries besides the US? Say, Poland. It spends a lot on pharmaceuticals – but on the right drugs?

http://www.euronews.com/2017/12/18/poland-spends-billions-on-drugs-but-are-they-the-right-ones-

Then, more on opioids. Ravaged by Opioids!

Away from the young, and to the old: could drugs slow ageing?

“Some pharmaceutical companies are exploring whether [certain] genetic traits could be used to create anti-ageing drugs.”

http://www.bbc.co.uk/news/health-42273362

*

And in BC, Canada: illicit placenta and stem cell therapies were seized!!!

http://www.cbc.ca/news/canada/british-columbia/illicit-placenta-and-stem-cell-therapies-seized-from-b-c-beauty-shop-1.4459518

‘The drugs confiscated from Before & After Beauty Lab on Hazelbridge Way “may pose serious risks to health,” according to a Health Canada press release.’

*

There was a also mysterious double murder in the world of Big Pharma!

*

Here at Strathclyde, CMAC welcomes Pfizer as newest partner…

https://www.strath.ac.uk/whystrathclyde/news/cmacwelcomespfizerasnewestpartner/

“CMAC (Continuous Manufacturing and Advanced Crystallisation), a pre-competitive consortium led by the University of Strathclyde to accelerate progress in pharmaceutical manufacturing, announces that Pfizer Inc has joined as a strategic member, alongside GSK, AZ, Novartis, Bayer, Takeda, Lilly and Roche.”

*

Lastly, St Thomas University (Canada) is hiring a cannabis/marijuana scholar. As the cannabis industry consolidates and the medicine is refined further, the job is a useful chance to contribute to the discussion. And it looks spectacular.

2017-12-15 Final REVISED Cannabis HRC advertisement

*

Here is a flyer for my book on Big Pharma! Cheap, cheap, cheap.

Richert_Flyer_2017

*

Big Pharma Round-Up

A round up of the recent Big Pharma and FDA stories.

Antibiotics in Farm Animals Drop:

https://www.theatlantic.com/health/archive/2017/12/antibiotics-farm-animal/547904/

Teva Pharmaceuticals is being reshaped:

Rebooting the FDA:

https://www.politico.com/agenda/story/2017/12/13/fda-approval-alternatives-000593

On AstraZeneca:

https://www.digitallook.com/news/broker-recommendations/astrazenecas-drug-pipeline-call-reinforces-barclays-top-pick-in-sector–3031953.html

 

Top 5 Stories of 2017:

https://investingnews.com/daily/life-science-investing/pharmaceutical-investing/5-top-pharmaceutical-stories-2017/

FDA clears the Apple watch:

The FDA is going to go after price gouging:

And supplement makers:

Bipartisanship on Drug Prices:

https://www.bloomberg.com/news/articles/2017-12-14/bipartisan-approach-on-drug-prices-emerging-after-health-fights

https://www.medscape.com/viewarticle/890002

*

I’ve more than likely missed some angles and stories. Drop me a line if you have suggestions.

*

Here’s a flyer for 30% off my Big Pharma book!

Richert_Flyer_2017